Combined administration of the GPVI-Fc fusion protein Revacept with low-dose thrombolysis in the treatment of stroke

BACKGROUND: Thrombolytic therapy with recombinant tissue plasminogen activator (rtPA) remains the only approved medication for acute ischemic stroke, but incurs significant bleeding risks. Therefore, approaches to combine lower doses of thrombolytic therapy with other effective drugs aim at improvin...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Heart Int
Huvudupphovsmän: Reimann, Andreas, Li, Zhongmin, Goebel, Silvia, Fassbender, Julia, Holthoff, Hans-Peter, Gawaz, Meinrad, Münch, Götz, Ungerer, Martin
Materialtyp: Artigo
Språk:Inglês
Publicerad: Wichtig 2016
Ämnen:
Original Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5072291/
https://ncbi.nlm.nih.gov/pubmed/27924212
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5301/heartint.5000229
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk